[NL] MEB: Follow-up reports of bradycardia with Telfast (STP-Free)

Home > News > European news > [NL] MEB: Follow-up reports of bradycardia with Telfast (STP-Free)

[NL] MEB: Follow-up reports of bradycardia with Telfast (STP-Free)

The MEB examined and discussed reports suggesting an association between the use of fexofenadine (Telfast) and bradycardia (slowed heart rate) in the Pharmacovigilance Working Party of the European Medicines Agency in London.

read full article

The European Medicines Agency on Twitter

The European Medicines Agency have created a news feed on Twitter (https://twitter.com/EMA_News). However, some companies have chosen to block access to Twitter for employees. To help regulatory professionals in those companies, we render recent items from their news feed on our site, for accessibility.